Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Carparts.Com Inc (PRTS) Price & Performance

Citius Pharmaceuticals IncTrade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Carparts.Com Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Carparts.Com Inc trades at $8.6 (market cap $66.42M). The key difference: Carparts.Com Inc is far larger — about 4.9× Citius Pharmaceuticals Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Carparts.Com Inc for 45 Days on average.

CTXRPRTS
Market Cap
$13.62M$66.42M
Volume
132,43840,287
Sector
HealthConsumer Cyclical
52-Week High
$1.82$10.00
52-Week Low
$0.48$3.88
Typical Hold Time
16 Days45 Days
Enterprise Value
$3.79M$79.39M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.

The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.

Carparts.Com Inc

CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.

The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CTXR
2% Buy98% Sell
Avg holding period · 16 Days
PRTS
0% Buy100% Sell
Avg holding period · 45 Days

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR →

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS →